Lauschke VM

Family name	Lauschke
Given name	Volker M
Initials	VM
ORCID	ORCID 0000-0002-1140-6204
Affiliations	Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

PubMed DOI Crossref

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK

Park Y, Lenk HÇ, Zhou Y, Lauschke VM, Molden E

The Lancet Psychiatry 13 (10) 852-860 [2026-10-00; online 2026-10-00]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Setting.

Park Y, Zhou Y, Lauschke VM

Clin. Pharmacol. Ther. 120 (2) 412-419 [2026-08-00; online 2026-04-14]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Prediction of drug hypersensitivity by comprehensive modeling of HLA-peptidomes.

Zhong Y, Lauschke VM, Wang Y, Zhou Y

Brief. Bioinformatics 27 (4) - [2026-07-03; online 2026-07-03]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Feed-Forward Deep Neural Networks Predict Substrate-Specific Effects of Transporter Variants to Explain Drug Response Variability.

Park Y, Zhou Y, Xiao M, Nies AT, Lauschke VM

Clin Transl Sci 19 (5) e70592 [2026-05-00; online 2026-05-09]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Engineering biomimetic tissue barrier models on chips: From design and fabrication to applications in disease modeling and drug screening.

Nasiri R, Madadelahi M, Nikmaneshi MR, ..., Khademhosseini A, Herland A

Biomaterials 327 (-) 123739 [2026-04-00; online 2025-09-23]

PubMed DOI Crossref

Substrate-specificity of pharmacogenomic variability - clinical relevance and emerging predictive strategies.

Zhou Y, Park Y, Lauschke VM

Expert Opin Drug Metab Toxicol 22 (3) 201-215 [2026-03-00; online 2026-04-02]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease - toward Streamlining Drug Discovery with Patient-Derived Assays.

Youhanna S, Taebnia N, Liang Y, ..., Michel M, Lauschke VM

Adv Biol (Weinh) 9 (12) e00337 [2025-12-00; online 2025-11-07]

PubMed DOI Crossref

Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.

De Mattia E, Park Y, Peruzzi E, ..., Lauschke VM, Cecchin E

Oncogene 44 (45) 4352-4362 [2025-11-00; online 2025-09-25]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Author Correction: Estrogen receptor activation remodels TEAD1 gene expression to alleviate hepatic steatosis.

Sommerauer C, Gallardo-Dodd CJ, Savva C, ..., Williams C, Kutter C

Mol Syst Biol 21 (9) 1282-1283 [2025-09-00; online 2025-06-12]

Claudia Kutter Erdinc Sezgin SciLifeLab Fellow

PubMed DOI Crossref

Evaluating the synergistic use of advanced liver models and AI for the prediction of drug-induced liver injury.

Zhou Y, Zhong Y, Lauschke VM

Expert Opin Drug Metab Toxicol 21 (5) 563-577 [2025-05-00; online 2025-02-02]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance.

Tremmel R, Pirmann S, Zhou Y, Lauschke VM

Br J Clin Pharmacol 91 (2) 252-263 [2025-02-00; online 2023-10-16]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Molecular docking to investigate HLA-associated idiosyncratic drug reactions.

Li K, Lauschke VM, Zhou Y

Drug Metab Rev 57 (1) 67-90 [2025-02-00; online 2025-01-20]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.

Tremmel R, Zhou Y, Camara MD, ..., Eliasson E, Lauschke VM

Nucleic Acids Res. 53 (D1) D1498-D1509 [2025-01-06; online 2024-11-14]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.

Youhanna S, Kemas AM, Wright SC, ..., Sundström M, Lauschke VM

Adv Sci (Weinh) 12 (3) e2407572 [2025-01-00; online 2024-11-28]

PubMed DOI Crossref

APF2: an improved ensemble method for pharmacogenomic variant effect prediction.

Zhou Y, Pirmann S, Lauschke VM

Pharmacogenomics J. 24 (3) 17 [2024-05-27; online 2024-05-27]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Population-specific variations in KCNH2 predispose patients to delayed ventricular repolarization upon dihydroartemisinin-piperaquine therapy.

Camara MD, Zhou Y, Dara A, ..., Gil PJ, Lauschke VM

Antimicrob. Agents Chemother. 68 (5) e0139023 [2024-05-02; online 2024-03-28]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments.

Kemas AM, Zandi Shafagh R, Taebnia N, ..., Hofmann U, Lauschke VM

Adv Healthc Mater 13 (11) e2303561 [2024-04-00; online 2023-12-10]

PubMed DOI Crossref

Estrogen receptor activation remodels TEAD1 gene expression to alleviate hepatic steatosis.

Sommerauer C, Gallardo-Dodd CJ, Savva C, ..., Williams C, Kutter C

Mol Syst Biol 20 (4) 374-402 [2024-04-00; online 2024-03-08]

Claudia Kutter Erdinc Sezgin SciLifeLab Fellow

PubMed DOI Crossref

Next-generation sequencing in pharmacogenomics - fit for clinical decision support?

Zhou Y, Lauschke VM

Expert Rev Clin Pharmacol 17 (3) 213-223 [2024-03-00; online 2024-01-23]

DDLS Fellow Yitian Zhou

DOI Crossref

SAG1.3-derived Frizzled-targeting negative allosteric modulators

Schulte G, Grätz L, Turku A, ..., Löber S, Gmeiner P

- - (-) - [2024-02-20; online 2024-02-20]

DOI Crossref

Estrogen receptor activation remodels TEAD1 gene expression to alleviate nonalcoholic fatty liver disease

Sommerauer C, Gallardo-Dodd CJ, Savva C, ..., Williams C, Kutter C

- - (-) - [2023-09-08; online 2023-09-08]

Claudia Kutter Erdinc Sezgin SciLifeLab Fellow

PubMed DOI Crossref

Structural variation of the coding and non-coding human pharmacogenome.

Tremmel R, Zhou Y, Schwab M, Lauschke VM

NPJ Genom Med 8 (1) 24 [2023-09-08; online 2023-09-08]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.

Khor CC, Winter S, Sutiman N, ..., Chowbay B, Schroth W

Clin. Pharmacol. Ther. 113 (3) 712-723 [2023-03-00; online 2023-01-31]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing.

Zhou Y, Koutsilieri S, Eliasson E, Lauschke VM

Basic Clin. Pharmacol. Toxicol. 131 (6) 452-464 [2022-12-00; online 2022-08-22]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.

Zhou Y, Lauschke VM

Pharmacogenomics J. 22 (5-6) 284-293 [2022-12-00; online 2022-09-06]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.

Zhou Y, Lauschke VM

Hum. Genet. 141 (6) 1113-1136 [2022-06-00; online 2021-10-15]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.

Dagli-Hernandez C, Borges JB, Marçal EDSR, ..., Hirata MH, Hirata RDC

Pharmaceutics 14 (5) - [2022-04-27; online 2022-04-27]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Hirata TDC, Dagli-Hernandez C, Genvigir FDV, ..., Hirata MH, Hirata RDC

Mol Diagn Ther 25 (6) 735-755 [2021-11-00; online 2021-08-06]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.

Zhou Y, Arribas GH, Turku A, ..., Gastaldello S, Lauschke VM

Sci Adv 7 (36) eabi6856 [2021-09-03; online 2021-09-01]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

Stebbing J, Sánchez Nievas G, Falcone M, ..., Abizanda P, Lauschke VM

Sci Adv 7 (1) - [2021-01-00; online 2021-01-01]

Claudia Kutter SciLifeLab Fellow

PubMed DOI Crossref

Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.

Zhou Y, Dagli Hernandez C, Lauschke VM

Br. J. Cancer 123 (12) 1782-1789 [2020-12-00; online 2020-09-25]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Impact of variants in ATP-binding cassette transporters on breast cancer treatment.

Xiao Q, Zhou Y, Lauschke VM

Pharmacogenomics 21 (18) 1299-1310 [2020-12-00; online 2020-11-23]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.

Xiao Q, Zhou Y, Winter S, ..., Schwab M, Lauschke VM

Int. J. Cancer 146 (9) 2475-2487 [2020-05-01; online 2020-02-17]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Ethnogeographic and inter-individual variability of human ABC transporters.

Xiao Q, Zhou Y, Lauschke VM

Hum. Genet. 139 (5) 623-646 [2020-05-00; online 2020-03-23]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1).

Russell LE, Zhou Y, Lauschke VM, Kim RB

Mol. Pharm. 17 (4) 1170-1181 [2020-04-06; online 2020-03-10]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.

Lauschke VM, Nordling Å, Zhou Y, ..., Barragan I, Ingelman-Sundberg M

Pharmacogenomics 20 (15) 1085-1092 [2019-10-00; online 2019-10-08]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

An optimized prediction framework to assess the functional impact of pharmacogenetic variants.

Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM

Pharmacogenomics J. 19 (2) 115-126 [2019-04-00; online 2018-09-12]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.

Zhou Y, Mägi R, Milani L, Lauschke VM

J. Lipid Res. 59 (10) 1987-2000 [2018-10-00; online 2018-08-03]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews.

Zhou Y, Lauschke VM

J. Med. Genet. 55 (9) 617-627 [2018-09-00; online 2018-07-03]

DDLS Fellow Yitian Zhou

PubMed DOI Crossref

Integrating rare genetic variants into pharmacogenetic drug response predictions.

Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM

Hum Genomics 12 (1) 26 [2018-05-25; online 2018-05-25]

DDLS Fellow Yitian Zhou

Lauschke VM

40 publications